Clinical trials: Real World Study
Asthma
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and…
- Trial name
- AIRITY (NCT07556159)
- Testing
- Procedure: Investigational Procedures
- Where
- 71 sites in United States, Canada and 3 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
PTA (Percutaneous Transluminal Angioplasty ), Femoropopliteal Artery Disease
Clinical Outcomes of GENOSS PCB for Femoropopliteal Artery Disease
The GENOSS PCB study aims to evaluate the safety and efficacy of a Paclitaxel-coated PTA Balloon Catheter(GENOSS® PCB) in patients with the femoropopliteal artery disease.
- Trial name
- GENOSS PCB (NCT07399080)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Genoss Co., Ltd.
Non-valvular Atrial Fibrillation (NVAF)
A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)
This study is planned to collect prospective data and evaluate the safety and effectiveness of rivaroxaban for the prevention of stroke and systemic embolism in Indian patients with NVAF when used in clinical practice under…
- Trial name
- XARIN (NCT03887780)
- Testing
- Rivaroxaban (Xarelto,Bay 59-7939)
- Where
- India
- Volunteers
- 504 people
- Sponsor
- Bayer
Metastatic HR+/HER2- Breast Cancer
A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer
The main aim of this study was to describe the profile of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) patients who received first-line (1L) current…
- Trial name
- NCT07086196
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients
The aim of this study was to collect existing information from the medical charts of patients enrolled in the ongoing asciminib Managed Access Program (MAP) to better understand the effectiveness and safety of asciminib when used…
- Trial name
- ASCERTAIN (NCT07644351)
- Where
- 18 sites in United States, Australia and 10 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)
The purpose of this study is to investigate glycaemic control and other clinical parameters in glucagon like peptide -1 (GLP-1) naive adult participants with type 2 diabetes (T2D) who initiated once weekly (OW) semaglutide in…
- Trial name
- MIRAGE (NCT05468632)
- Testing
- Semaglutide
- Where
- 17 sites in North Macedonia
- Volunteers
- 314 people
- Sponsor
- Novo Nordisk A/S
Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs)
HEAL-4: Real-World Effectiveness of 4 Amniotic Allografts Adjunctive to Standard Care in DFU, VLU, and PU
This retrospective multi-site observational cohort study uses electronic health records (EHR) from U.S. wound care centers to evaluate the effectiveness of four amniotic membrane allografts (Acesso DL, Acesso TL, Neostim DL…
- Conditions
- Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
- Trial name
- HEAL-4 (NCT07223515)
- Where
- 2 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Dynamic Medical Services dba Acesso Biologics
Infection
Real-World Observational Study Of Zavicefta to Characterize Use Patterns
This is a non-interventional medical chart review study aiming to examine the treatment patterns, effectiveness, and safety of ceftazidime-avibactam in approximately 12 countries (including but not limited to Austria, France…
- Trial name
- EZTEAM (NCT03923426)
- Testing
- Zavicefta Treatment
- Where
- 45 sites in Argentina, Austria and 9 more
- Volunteers
- 572 people
- Sponsor
- Pfizer
Breast Neoplasms, Breast Cancer
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
This is a prospective non-interventional, multicenter study observing patient reported outcomes as well as real-world efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with documented Human epidermal growth factor…
- Conditions
- Breast Neoplasms, Breast Cancer, Neoplasm Metastasis
- Trial name
- PROVIDENCE (NCT05573893)
- Where
- 109 sites in Germany
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)
PETRICHOR is a prospective, non-interventional, single-arm, multi-centre study in Germany evaluating real-world clinical and patient-reported outcomes in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), whose…
- Trial name
- PETRICHOR (NCT07633158)
- Where
- 19 sites in Germany
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia
The clonoSEQ® Watch Registry
This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL).
- Conditions
- Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
- Trial name
- NCT04545333
- Testing
- clonoSEQ Assay
- Where
- 14 sites in United States
- Volunteers
- 465 people
- Sponsor
- Adaptive Biotechnologies
Myelodysplastic Syndromes
A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept
The purpose of this study is to understand the treatment use of luspatercept in adults diagnosed with lower-risk myelodysplastic syndromes
- Trial name
- NCT07075406
- Testing
- Luspatercept
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Bristol-Myers Squibb
Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastasis
Pluvicto Real-world Investigation in Survival in Metastatic CRPC
This study aims to evaluate the various aspects of treatment effectiveness of [177Lu]Lu-PSMA-617 (Pluvicto) in mCRPC patients in both pre- and post-taxane settings.
- Trial name
- PRISM (NCT07697989)
- Where
- United States
- Volunteers
- 1,085 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia
Study Conducted Among Patients With CML
Retrospective, non-interventional observational cohort study conducted among patients with CML.
- Trial name
- NCT05476562
- Testing
- Tyrosine Kinase Inhibitors (TKIs)
- Where
- United States
- Volunteers
- 3,234 people
- Sponsor
- Novartis Pharmaceuticals
HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
Trastuzumab deruxtecan's (T-DXd's) efficacy and safety has been confirmed in traditional clinical trials, there is a lack of real-world evidence, especially among Chinese patients.
- Trial name
- RECOVER (NCT06846996)
- Testing
- Trastuzumab deruxtecan (T-DXd)
- Where
- 40 sites in China
- Volunteers
- 260 people
- Sponsor
- Daiichi Sankyo
ALK-positive Non-small-cell Lung Cancer
Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
To evaluate the clinical real world outcomes of lorlatinib in second/later line setting anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) to TKI sequence sequence treatment after failure of alectinib as a…
- Trial name
- NCT04979988
- Testing
- Lortlatinib
- Where
- 16 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Pfizer
Inflammatory Bowel Disease, Colitis, Ulcerative
A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab
The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting.
- Conditions
- Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn Disease
- Trial name
- LUNAR (NCT07532213)
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Janssen-Cilag A.G., Switzerland
Hepatitis C Virus (HCV)
Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response
Hepatitis C virus (HCV) infection is among the most common of all chronic liver diseases. HCV predominantly affects liver cells and causes the liver to become inflamed and damaged.
- Trial name
- CHOICE (NCT04577482)
- Where
- 10 sites in Russia
- Volunteers
- 42 people
- Sponsor
- AbbVie
Abdominal Aortic Aneurysm
Global Fenestrated Anaconda Clinical STudy
This study is a prospective non-interventional, multi-centre study of the Vascutek Fenestrated Anaconda™ system, and is essentially a post-market study.
- Trial name
- Global FACT (NCT03180996)
- Testing
- Vascutek Fenestrated Anaconda™ Custom AAA Stent Graft System
- Where
- 11 sites in Australia, Austria and 3 more
- Volunteers
- 160 people
- Sponsor
- Vascutek Ltd.
Non-squamous, Non-Small Cell Lung Cancer
The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
Non-interventional, multi-country, multi-centre cohort study based on existing data from medical records (paper or electronic) or electronic health records of patients with advanced NSCLC harbouring EGFR mutations and treated…
- Trial name
- UpSwinG (NCT04179890)
- Testing
- Afatinib (Gi(l)otrif®), Erlotinib (Tarceva®), Gefitinib (IRESSA®)
- Where
- United Kingdom
- Volunteers
- 462 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.